The Penn Heart Failure Study (over 1100 chronic HF patients) demonstrated that sST2 is a powerful indicator of prognosis and provides moderate improvement in risk stratification when added to conventional biomarkers like BNP or atrial natriuretic peptide [15]. The gene discussed is NPPB; the disease is heart failure.